Consolidated Statements of Income and
Comprehensive Income/Loss (-)
|
Year ended December 31 |
|
|
|---|---|---|---|
(thousands of €, except per share data) |
2025 |
2024 |
Notes |
Supply revenues |
29,924 |
34,863 |
|
Collaboration revenues |
1,082,324 |
240,786 |
|
Total net revenues |
1,112,248 |
275,649 |
|
|
|
|
|
Cost of sales |
(29,736) |
(34,863) |
|
Research and development expenses |
(459,421) |
(335,459) |
|
Sales and marketing expenses |
(6,100) |
(17,193) |
|
General and administrative expenses |
(147,333) |
(117,245) |
|
Impairment of the cell therapy activities |
(228,112) |
– |
|
Other operating income |
53,493 |
40,773 |
|
|
|
|
|
Operating profit/loss (-) |
295,039 |
(188,338) |
|
|
|
|
|
Fair value adjustments and net currency exchange differences |
(39,356) |
95,795 |
|
Other financial income |
48,051 |
91,128 |
|
Other financial expenses |
(2,863) |
(1,670) |
|
|
|
|
|
Profit/loss (-) before tax |
300,871 |
(3,085) |
|
|
|
|
|
Income taxes |
18,621 |
1,803 |
|
|
|
|
|
Net profit/loss (-) from continuing operations |
319,492 |
(1,282) |
|
|
|
|
|
Net profit from discontinued operations, net of tax |
1,392 |
75,364 |
|
|
|
|
|
Net profit |
320,884 |
74,082 |
|
|
|
|
|
Net profit attributable to: |
|
|
|
Owners of the parent |
320,884 |
74,082 |
|
Basic and diluted earnings per share |
4.87 |
1.12 |
|
Basic and diluted earnings/loss (-) per share from continuing operations |
4.85 |
(0.02) |
|
The accompanying notes form an integral part of these financial statements.
|
Year ended December 31 |
|
|
|---|---|---|---|
(thousands of €) |
2025 |
2024 |
Notes |
Net profit |
320,884 |
74,082 |
|
Items that will not be reclassified subsequently to profit or loss: |
|
|
|
Re-measurement of defined benefit obligation |
653 |
246 |
|
Fair value adjustment financial assets held at fair value through other comprehensive income |
(6,132) |
2,486 |
|
Items that may be reclassified subsequently to profit or loss: |
|
|
|
Translation differences, arisen from translating foreign activities |
(475) |
578 |
|
Realization of translation differences upon sale of foreign operations |
– |
4,095 |
|
|
|
|
|
Other comprehensive income/loss (-), net of income tax |
(5,954) |
7,405 |
|
|
|
|
|
Total comprehensive income attributable to: |
|
|
|
Owners of the parent |
314,930 |
81,487 |
|
|
|
|
|
Total comprehensive income attributable to owners of the parent arises from: |
|
|
|
Continuing operations |
313,538 |
1,764 |
|
Discontinued operations |
1,392 |
79,723 |
|
Total comprehensive income, net of income tax |
314,930 |
81,487 |
|
The accompanying notes form an integral part of these financial statements.